文献速递妇科

腹腔镜手术评分算法用于分诊晚期卵巢癌肿瘤减灭术时机

Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer.
PubMed 文献 · Obstet Gynecol · 2018-01-01

研究前瞻性纳入疑似晚期卵巢癌患者,用腹腔镜评分算法将预测指数值<8分者分诊至初次手术、≥8分者接受新辅助化疗;初次手术组完全肉眼切除率88%高于新辅助化疗组74%,无进展生存期21.4个月优于12.9个月(P<.001)。

要点

  • 预测指数值<8分者行初次手术,≥8分者接受新辅助化疗。
  • 两名外科医生盲法评分不一致率仅2%。
  • 初次手术组无进展生存期21.4个月优于新辅助化疗组12.9个月(P<.001)。

核心结论

  • 腹腔镜分诊评估使晚期卵巢癌患者获得个体化管理,并在肿瘤减灭术中实现高完全切除率。

研究设计与样本

  • 前瞻性研究,2013年4月至2016年12月对疑似晚期卵巢癌患者行腹腔镜评估,共评估621例,488例符合纳入标准,其中215例接受腹腔镜评分。
  • 采用经验证的评分方法由两名外科医生盲法评分,预测指数值<8分者行初次手术,≥8分者接受新辅助化疗。
  • 对无进展生存期进行单因素和多因素分析。

主要发现

  • 215例接受腹腔镜评分者中,125例预测指数值<8分,84例预测指数值≥8分。
  • 两名外科医生盲法预测指数值评分不一致率仅2%。
  • 初次手术组88%患者达到无肉眼残留病灶(R0切除),新辅助化疗组为74%。
  • 初次手术组分诊后无进展生存期21.4个月,优于新辅助化疗组的12.9个月(P<.001)。
  • 按治疗组和残留病灶状态,中位无进展生存期分别为:初次手术-R0 23.5个月;初次手术-R1(任何肉眼残留病灶)17.6个月;新辅助化疗-R0 15.5个月;新辅助化疗-R1 12.9个月(P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the effects of a laparoscopic scoring algorithm to triage patients with advanced ovarian cancer to immediate or delayed debulking to improve complete gross surgical resection rates and determine the resulting clinical outcomes. METHODS: We prospectively performed laparoscopic assessment on patients with suspected advanced-stage ovarian cancer from April 2013 to December 2016 to determine primary resectability at tumor reductive surgery. Patients with medically inoperable or distant metastatic disease received neoadjuvant chemotherapy. Two-surgeon scoring was performed in a blinded fashion using a validated scoring method. Patients with predictive index value scores less than 8 were offered primary surgery and those with scores 8 or greater received neoadjuvant chemotherapy. Univariate and multivariate analysis was performed for effects on progression-free survival. RESULTS: Six hundred twenty-one patients presenting with presumed advanced ovarian cancer were evaluated during the study period and 488 patients met inclusion criteria. Two hundred fifteen patients underwent laparoscopic scoring, of whom 125 had predictive index value scores less than 8 and 84 had predictive index value scores 8 or greater. Blinded two-surgeon predictive index value scoring resulted in bivariate discordance in only 2% of patients. Tumor cytoreduction led to no gross residual disease (R0 resection) in 88% of patients in the primary surgery group and 74% in the neoadjuvant chemotherapy group. Patients triaged to primary surgery had an improved progression-free survival of 21.4 months versus 12.9 months in those patients undergoing neoadjuvant chemotherapy (P<.001). Median progression-free survival by treatment group and residual disease status was as follows: primary surgery-R0 23.5 months; primary surgery-R1 (any gross residual disease) 17.6 months; neoadjuvant chemotherapy-R0 15.5 months; and neoadjuvant chemotherapy-R1 12.9 months (P<.001). On multivariate analysis for progression-free survival, baseline CA 125 (P=.001) and gross residual disease at tumor reductive surgery (P=.01) were significantly associated with progression-free survival. CONCLUSION: Laparoscopic triage assessment allowed for a personalized approach to the management of patients with advanced ovarian cancer and resulted in high complete surgical resection rates at tumor reductive surgery.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Fleming ND, Nick AM, Coleman RL, et al. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol. 2018. PMID: 30095787. doi:10.1097/AOG.0000000000002796

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。